Southern Asia: Medicaments Containing Insulin Market 2024

Medicaments Containing Insulin Market Size in Southern Asia

In 2023, after two years of growth, there was decline in the South Asian medicaments containing insulin market, when its value decreased by X% to $X. In general, consumption, however, showed resilient growth. Over the period under review, the market hit record highs at $X in 2016; however, from 2017 to 2023, consumption failed to regain momentum.

Medicaments Containing Insulin Production in Southern Asia

In value terms, medicaments containing insulin production shrank slightly to $X in 2023 estimated in export price. In general, production, however, saw a relatively flat trend pattern. The most prominent rate of growth was recorded in 2016 with an increase of X%. Over the period under review, production hit record highs at $X in 2013; however, from 2014 to 2023, production failed to regain momentum.

Medicaments Containing Insulin Exports

Exports in Southern Asia

Medicaments containing insulin exports fell notably to X kg in 2023, waning by X% on 2022. In general, exports saw a dramatic decrease. The pace of growth was the most pronounced in 2022 with an increase of X% against the previous year. The volume of export peaked at X tons in 2013; however, from 2014 to 2023, the exports stood at a somewhat lower figure.

In value terms, medicaments containing insulin exports fell significantly to $X in 2023. Overall, exports continue to indicate a precipitous decline. The growth pace was the most rapid in 2022 with an increase of X%. The level of export peaked at $X in 2013; however, from 2014 to 2023, the exports remained at a lower figure.

Exports by Country

India (X kg) and Bangladesh (X kg) were the largest exporters of medicaments containing insulin but not antibiotics in 2023, reaching near X% and X% of total exports, respectively. It was distantly followed by Pakistan (X kg), committing a X% share of total exports.

From 2012 to 2023, the biggest increases were recorded for Bangladesh (with a CAGR of X%), while shipments for the other leaders experienced a decline in the exports figures.

In value terms, the largest medicaments containing insulin supplying countries in Southern Asia were Pakistan ($X), India ($X) and Bangladesh ($X).

Among the main exporting countries, Bangladesh, with a CAGR of X%, recorded the highest growth rate of the value of exports, over the period under review, while shipments for the other leaders experienced a decline in the exports figures.

Export Prices by Country

In 2023, the export price in Southern Asia amounted to $X per ton, jumping by X% against the previous year. Over the period under review, the export price, however, continues to indicate a noticeable decline. The most prominent rate of growth was recorded in 2015 when the export price increased by X% against the previous year. Over the period under review, the export prices reached the maximum at $X per ton in 2017; however, from 2018 to 2023, the export prices remained at a lower figure.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was Pakistan ($X per ton), while Bangladesh ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Bangladesh (X%), while the other leaders experienced mixed trends in the export price figures.

Medicaments Containing Insulin Imports

Imports in Southern Asia

Medicaments containing insulin imports declined rapidly to X kg in 2023, shrinking by X% on the previous year's figure. Over the period under review, imports, however, saw a strong expansion. The pace of growth appeared the most rapid in 2022 when imports increased by X%. The volume of import peaked at X tons in 2018; however, from 2019 to 2023, imports stood at a somewhat lower figure.

In value terms, medicaments containing insulin imports shrank dramatically to $X in 2023. Overall, imports, however, recorded a relatively flat trend pattern. The pace of growth was the most pronounced in 2022 when imports increased by X%. As a result, imports reached the peak of $X, and then reduced rapidly in the following year.

Imports by Country

In 2023, Nepal (X kg) and Sri Lanka (X kg) were the largest importers of medicaments containing insulin but not antibiotics in Southern Asia, together comprising X% of total imports. It was distantly followed by Bangladesh (X kg), mixing up a X% share of total imports.

From 2012 to 2023, the biggest increases were recorded for Sri Lanka (with a CAGR of X%), while purchases for the other leaders experienced mixed trends in the imports figures.

In value terms, Bangladesh ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in Southern Asia, comprising X% of total imports. The second position in the ranking was taken by Nepal ($X), with a X% share of total imports.

In Bangladesh, medicaments containing insulin imports remained relatively stable over the period from 2012-2023. The remaining importing countries recorded the following average annual rates of imports growth: Nepal (X% per year) and Sri Lanka (X% per year).

Import Prices by Country

In 2023, the import price in Southern Asia amounted to $X per ton, with a decrease of X% against the previous year. In general, the import price recorded a deep downturn. The pace of growth was the most pronounced in 2016 when the import price increased by X%. The level of import peaked at $X per ton in 2022, and then shrank rapidly in the following year.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was Bangladesh ($X,600 per ton), while Sri Lanka ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Bangladesh (X%), while the other leaders experienced mixed trends in the import price figures.

Source: IndexBox Platform